BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

BOULDER, Colo., March 27, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

Data from Phase 1 clinical trial supports advancing cobomarsen, or MRG-106, into a Phase 2 potentially registrational clinical trial for CTCL (the SOLAR trial)Completed Phase 1 clinical trial of MRG-2...

BOULDER, Colo., March 07, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

BOULDER, Colo., March 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...